• Astiva Health is revolutionizing patient involvement in healthcare, particularly for the aging population
• Beyond offering healthcare services, Astiva is dedicated to creating a supportive health community
• With patients at the center, Astiva Health is transforming aging healthcare into a proactive, participatory experience

The United States is in the midst of a global demographic shift toward an aging population, with the U.S. Census Bureau projecting that by 2034, adults aged 65 and older will outnumber children under the age of 18 for the first time in U.S. history (https://ibn.fm/yGoyH). With this shift, the demand for a more holistic approach to healthcare has never been more critical. Astiva Health stands at the forefront of this transformation, championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods.

This shift toward patient-centered care and the creation of a robust support network marks a significant departure from conventional healthcare models, aligning with the growing need to adapt to the complexities of aging in a rapidly evolving world.

At the core of Astiva Health’s innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences, needs and values guide their care plans. This shift not only acknowledges patients as essential partners in their health journey but also aligns with research demonstrating the benefits of patient-centric care, including improved health outcomes, enhanced patient satisfaction, and potential cost reductions through minimized unnecessary interventions.

A critical element in Astiva Health’s strategy is the development of a supportive health community. This community — encompassing healthcare professionals, family, caregivers and peer groups — provides a comprehensive network of resources and support. Such a community-focused approach facilitates knowledge exchange and is particularly advantageous in managing chronic conditions, which are prevalent among older adults.

Astiva Health’s proactive healthcare model extends beyond basic services, offering a wide range of resources addressing the physical, mental and social facets of health. Initiatives such as fitness programs, grocery benefits, nutritional guidance, easily accessible transportation services and mental health support aim to promote a healthy lifestyle. These resources play a pivotal role in maintaining independence, enhancing the quality of life and potentially preventing severe health issues.

Technology plays a crucial role in Astiva Health’s mission to deliver patient-centric care and build a supportive health community. Innovations such as telehealth services are central to this effort, enabling remote consultations and promoting active health management. This approach fosters a more accessible, efficient and personalized healthcare experience for older adults, ensuring that patients can manage their health effectively even from a distance. Astiva Health’s strategic use of technology is designed to enhance patient engagement and autonomy, making healthcare more adaptable to the needs of the aging population.

Astiva Health is not merely addressing diseases; it’s advocating for a comprehensive, proactive approach to health that places individuals in command of their well-being. The organization’s dedication to fostering a supportive health community and providing diverse resources underscores its commitment to redefining aging healthcare. By prioritizing patient involvement and embracing technology, Astiva Health is setting a new standard for effective, fulfilling and sustainable healthcare for the aging population.

This paradigm shift in aging healthcare, championed by Astiva Health, highlights the significance of each individual’s unique journey and the collective effort required to support it. It envisions a healthcare ecosystem that transcends medical treatment to foster community, purpose and well-being among older adults. Through collaboration, innovation and unwavering commitment to patient-centric care, Astiva Health is ensuring a future where aging individuals not only live longer but also thrive in their golden years.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Fr8Tech recently participated in the Geotab Connect 2024 event as a marketplace partner, covering insights into connected vehicles, data intelligence, artificial intelligence, and sustainability
• Last year, the company integrated its Fr8App freight-matching platform with Geotab’s open API, boosting real-time visibility and efficiency for shippers and carriers
• Fr8Tech recently secured a cross-border logistics services contract with Kawasaki Motores de Mexico, a division of manufacturing conglomerate Kawasaki Heavy Industries, Ltd.

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process and freight logistics, recently participated in the prestigious Geotab Connect 2024 event as a distinguished marketplace partner. The Geotab Connect 2024 took place in Las Vegas February 14 to 16, 2024, delivering unparalleled insights into the ever-evolving landscape of connected vehicles, data intelligence, artificial intelligence, and sustainability (https://ibn.fm/jbgKE).

“We are thrilled to continue being marketplace partners with such a prominent company in the technology and logistics industry like Geotab. Fr8App has been able to significantly enhance the user experience for shippers and carriers on its platform with Geotab’s telematics, and we look forward to bringing further innovation to our customers and partners through collaboration and contribution to Geotab’s ecosystem,” commented Javier Selgas, CEO of Fr8Tech and Fr8App.

Fr8Tech last September announced that it had integrated its Fr8App freight-matching platform with Geotab’s open application programming interface (“API”) (https://ibn.fm/uUQoD). According to the company, this integration was intended not only to boost substantially real-time visibility and efficiency for carriers and shippers but also to ensure that clients enjoy added capabilities through the Fr8App platform. The integration exemplifies Fr8App’s continuous improvement and Fr8Tech’s investment in new features, which, besides being a source of pride for the company, have enabled it to secure contracts with global industry leaders to revolutionize their respective cross-border logistics operations.

Recently, Fr8Tech celebrated the execution of a cross-border logistics services contract with Kawasaki Motores de Mexico. Under the terms of the contract, Fr8Tech is mandated with directing and coordinating the cross-border logistics for Kawasaki’s iconic Jet Ski models via the Fr8App platform, showcasing the platform’s adaptability and efficiency in meeting a wide range of clients’ transportation needs and requirements (https://ibn.fm/vOuC6).

For Kawasaki Motores de Mexico, the contract represents a deliberate strategic decision to go beyond basic technology adoption. “We believe Fr8App aligns seamlessly with our core values of innovation and efficiency. Awarding this contract signifies more than just a technological advancement; it represents a strategic leap forward in how we approach our logistics operations. Together with Fr8App, we are eager to embark on a journey toward achieving unparalleled efficiency, reliability, and substantial cost reduction,” stated Daniel Ortiz, Logistic Operation Supervisor of Kawasaki Motores de Mexico.

Kawasaki Motores de Mexico is a division of Kawasaki Heavy Industries, Ltd., a multinational conglomerate with a rich 120-year heritage of manufacturing heavy equipment, marine vessels (liquid natural gas carriers, high-speed vessels, and other future-oriented marine technologies), motorcycles, engines, aerospace and defense equipment, and rolling stock.

“This contract with Kawasaki Motores de Mexico is a testament to our commitment to delivering cutting-edge solutions to a wide variety of industries. We believe that by securing a contract with Kawasaki Motores de Mexico, we also gain a chair at the table for a broader set of opportunities with many of the Kawasaki companies across North America,” conveyed Selgas.

This strategy, Selgas explained, has served the company well with other conglomerates. It has enabled Fr8Tech to pursue additional opportunities with a large multinational conglomerate after forging an initial partnership; the company’s partnership with Kimberly Clark de Mexico, S.A.B. de C.V. (“KCM”), a Mexican company that manufactures and commercializes branded consumer products, perfectly embodies this strategy.

In February 2022, Fr8Tech announced it had secured its first contract with KCM for the then-newly launched Fr8Fleet dedicated truck and capacity planning platform (https://ibn.fm/OdA8j). By September 2022, the partnership had expanded to include the Fr8App platform for cross-border logistics for shipments from Mexico to the U.S. (https://ibn.fm/Iwsaw). A month later, Fr8Tech announced that it had received a two-year commitment from KCM to expand its Fr8Fleet product (https://ibn.fm/Iqtg8).

Having completed numerous strategic integrations with leading tech logistics companies, GPS providers, and industry partners that have expanded the reach and breadth of its systems operating environment, Fr8Tech is looking forward to pursuing the opportunities these integrations continue to unlock. Additionally, the company remains committed to further strengthening its global connectivity to meet the ever-changing demands of the freight logistics industry.

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• Video streaming revenue worldwide is expected to reach $137.70 billion by 2027 due to the growing user base adopting video streaming platforms
• Bravo recently entered an Asset Purchase Agreement to acquire assets of Streaming TVEE, Inc., with plans to launch TVee NOW(TM) during Q1 2024
• TVee NOW(TM) will offer traditional broadcast television, encompassing cable and satellite networks, through a joint venture with a third party, which is set to close at a later date
• TVee NOW(TM) will be available for download in the Roku Channel Store, Apple Store, and Google Play Store

Video streaming revenue worldwide has exploded over the last decade, with an estimated value of $108.50 billion in 2024. By 2027, the market is expected to reach $137.70 billion, growing at a CAGR of 8.27% from 2024 to 2027 (https://ibn.fm/X8qMy). This growth is supported by a fast-growing user base, thanks to the worldwide adoption of video streaming platforms. Bravo Multinational (OTC: BRVO), a company actively exploring opportunities in the entertainment, hospitality, and technology sectors, is exploring streaming to generate long-term value for its shareholders through high-growth business ventures.

Bravo recently announced entering into an Asset Purchase Agreement to acquire the assets of Streaming TVEE, Inc., solidifying its entry into the video streaming industry. The company’s strategic move establishes the business foundation for the previously announced flagship offering, TVee NOW(TM), which is expected to launch a Beta version during Q1 2024. The new streaming service will be available directly to consumers over the web on any Connected TV, smartphone, or tablet. The application will be available for download in the Roku Channel Store, Apple Store, and Google Play Store.

“Fueling this transformative journey is a commitment to technical innovation, where state-of-the-art features and cutting-edge technology converge to create a seamless and immersive streaming experience,” Bravo CEO Grant Cramer said (https://ibn.fm/WxsdQ). “Viewers can expect a user-friendly interface, enhanced streaming quality, and innovative features that elevate the entertainment quotient.”

TVee NOW(TM) intends to offer traditional broadcast television, encompassing cable and satellite networks, through a joint venture with a third party, which is set to close at a later date. The platform will also include various on-demand content, including but not limited to movies, shows/series, concerts, comedy specials, events, and more. TVee NOW(TM) also plans to supplement offerings with its own original and exclusive content.

The agreement also includes acquiring the OTT (Over-The-Top) streaming technology license. The technology is a hybrid model comprised of Advertising-based Video-on-Demand, programmatic advertising through ad servers, and Subscription-based Video-on-Demand – all of which the company plans to offer at competitive rates compared to other services.

“Having a robust technical foundation is paramount for us, with our goal of establishing multi-level monetization,” Bravo COO Kayla Slick said. “It’s an exciting step towards building a sustainable and rewarding ecosystem for everyone involved.”

A notable highlight of the Asset Purchase Agreement includes Streaming TVEE’s recent acquisition of MWP Entertainment Group’s video property assets. These assets include exclusive rights, image and likeness, label waivers, and exploitation rights for streaming 117 high-definition music and comedy performances, which offer a director’s cut and multiple camera perspectives. Some of the artists and comedians on the list include H.E.R., Jane’s Addiction, Snoop Dogg, Moonalice, Bill Burr, Jim Gaffigan, Kristen Schaal, Rob Delaney, and more.

For more information, visit the company’s website at www.BravoMultinationalInc.com.

NOTE TO INVESTORS: The latest news and updates relating to BRVO are available in the company’s newsroom at https://ibn.fm/BRVO

Scientists, C-level executives, managers, and directors from the drug discovery pharma and biotech industry verticals across Europe and North America are invited to attend the 19th BioPharma Drug Discovery Nexus Conference at the Basel, Mariott Hotel, Switzerland.

A highly respected conference, this is an invite-only event where top industry leaders and executives will explore the advancements and trends in the field of drug discovery. These experts share insights and strategies that highlight the path for the future of medicine.

From discussions to collaborations, this conference offers a phenomenal forum for discovering fresh perspectives and showcasing the latest technologies among a coveted audience of distinguished leaders and experts. Newbies can showcase their unique innovations while investors can look for new avenues of business. The presentations, speaker sessions, and even the coffee and lunch breaks, offer valuable opportunities for networking among the attendees.

Experts will also offer insights into the latest trends that are broadly applicable to several areas of medicine. Panel discussions will be held on topics like the impact of advanced drug development and breakthroughs in the field. Learn the latest trends and innovations in the realm of drug discovery, where important speakers discuss a wide range of topics, from achieving targets through AI to the scope of cell and gene therapy. The 19th Biopharma Drug Discovery Nexus offers an extensive platform for key insights, discoveries, and collaborative discussions on the intricacies of healthcare innovation.

Businesses, managers, and executives can connect with influencers to get tips and relevant solutions from the panel of expert speakers. The scope of networking opportunities amongst the rich and diverse audience is of special significance. Attendees can meet eminent industry leaders and peers to develop long-term connections and business ties.

To learn more, please visit https://ibn.fm/j43gD

• One in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls
• The SenseToKnow app accurately predicted eventual autism diagnoses in a group of 475 children – according to the study, performance was similar across sex, race, and ethnicity
• PaxMedica is leveraging historical data on the drug suramin to fund trials aimed at treating Autism Spectrum Disorder and Fragile X-Associated Tremor/Ataxia Syndrome

According to the CDC, about 1 in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls (https://ibn.fm/06kly). Currently, there is no medical test to diagnose ASD, and families often face a delay in receiving a diagnosis. Doctors must rely on developmental history and the behavior of the child to make an ASD diagnosis. A diagnosis in girls and children with minority backgrounds often has a longer wait time due to the challenges in finding appropriate experts and the variable symptoms that accompany the disorder.

In a study published in Nature Magazine, researchers introduced a digital screening device that uses machine learning to analyze different behavioral aspects to assess the likelihood of childhood ASD. The SenseToKnow app accurately predicted eventual autism diagnoses in a group of 475 children – according to the study, performance was similar across sex, race, and ethnicity (https://ibn.fm/d4xhR).

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is focusing its lead program on ASD, which there is no approved pharmacologic treatment targeting cause and symptoms. The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions.

PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African Trypanosomiasis (“HAT”), to support new studies for treating Autism Spectrum Disorder and a related condition known as Fragile X-Associated Tremor/Ataxia Syndrome (“FXTAS”). The original developer of suramin, the German company Bayer, had used it to treat HAT. Now, the U.S. Food and Drug Administration (“FDA”) is allowing PaxMedica to apply this old research to see if suramin can also help treat rare instances of HAT in Americans, typically caught during visits to Africa. If these trials prove that suramin is effective, PaxMedica could not only get the drug approved for use, but also receive a special coupon from the FDA called a Priority Review Voucher (“PRV”). This voucher, which can accelerate the review of a new drug, is quite valuable and could be sold to another pharmaceutical company for a significant amount of money. The company intends to channel these funds into conducting extensive trials for ASD and FXTAS treatment through its lead program, PAX-101(IV Suramin). These programs utilize a proprietary source of suramin, a century-old drug with broad therapeutic potential. Although initial FDA approval for suramin in treating sleeping sickness is anticipated within months, funding from the sale of the PRV will expedite PaxMedica’s autism application trials. The final approval for the drug’s use in treating autism may take a couple of years to materialize.

In 2024, PaxMedica is positioned to continue its momentum, sustained by achievements in 2023. The company is working to expand its product pipeline, centered on its proprietary source of suramin. PaxMedica technology is designed to help people with ASD integrate more successfully into society, enhancing their overall quality of life. PAX-101 and PAX-102’s promise extends beyond ASD, with potential applications in treating human African trypanosomiasis and other conditions characterized by intractable neurologic symptoms.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability
• This has earned it 39 granted patents, with many pending globally
• DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology. Its patented DehydraTECH(TM) technology has proven itself in numerous studies since 2016, highlighting its ability to increase bio-absorption compared to standard industry formulations while also reducing time of onset, as well as delivering drugs more effectively across the blood brain barrier (https://ibn.fm/CjpYF).

The technology’s effectiveness and uniqueness have earned it 39 granted patents, with many patents pending globally. DehydraTECH has a number of potential pharmaceutical applications, a testament to its versatility and overall effectiveness. The key factor that has played a role in its adoption is its unique ability to improve drug bioavailability, a critical marker and determinant in overall drug effectiveness.

Bioavailability can be described as the extent to which a substance or drug becomes entirely available for its intended biological destination ((https://ibn.fm/txE38). It may also be referred to as a measure of the rate and fraction of the initial drug dose that ultimately gets to the targeted part of the body (https://ibn.fm/etuHD). Usually, the higher the bioavailability, the more effective the drug, and since time immemorial, scientists have been exploring various ways to improve it.

Studies have highlighted several factors that have shown to affect drug bioavailability, particularly for orally administered drugs. These include decomposition of the medication in the lumen, hepatic fist-pass impact, surface and time accessible for retention, as well as pH and perfusion of the small digestive system.

Lexaria, through its DehydraTECH technology, enhances the performance of several categories of fat-soluble active molecules and drugs, ultimately improving their bioavailability and efficiency. This is achieved by mixing the active ingredients as a delivery “payload” with specific fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level. This is followed by integrating the newly combined molecules into end-product production across various dosage form factors (https://ibn.fm/u1eXo).

With this technology, Lexaria looks to tap into various growing markets, among them the cardiovascular drugs market and the diabetes markets, both projected to be valued at $115.8 billion and $134.1 billion by 2028 and 2030, respectively. It also hopes to make drugs more effective, possibly reducing the cost of treatment and the patients’ overall quality of life. The company is also aggressively pushing for its patent applications and approvals globally, a show of commitment to creating shareholder value. In addition to its focus on GLP-1 clinical studies for the 2024 calendar year, Lexaria is confident that it will carve out a decent market share for itself, ultimately making 2024 its biggest year yet.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Top executives, middle-level, and senior managers, working in clinical trial operations, outsourcing, digital health, patient engagement, and allied industries in the biopharma spectrum across Europe and North America, are invited to attend the 19th BioPharma Clinical Trials Nexus Conference at the Basel, Mariott Hotel, Switzerland.

A prestigious conference, this is an invite-only event featuring top executives and eminent industry leaders. The attendees discuss practical and progressive strategies that pave the path for future trends and outcomes. The platform offers a range of fresh ideas, showcasing the latest technologies and market trends, at a parade of company presentations.

Powerful speakers will address important topics giving solutions and fresh ideas that the audience can incorporate into their business. The 19th BioPharma Clinical Trials Nexus agenda includes an extensive line-up of experts showcasing company offerings and solutions involving pivotal subjects in the field of clinical trial management.

The conference commences with registration, followed by presentations and panel discussions that offer fresh perspectives and insights. Attendees can connect with peers, industry leaders, and influencers during group discussions, coffee, and lunch breaks. These connections are crucial in providing leads and business opportunities to the attendees.

This conference offers a robust forum for the invitees to develop meaningful business ties. With two days of networking among the industry giants, the event will witness the growth of strong business ties.

These business relations, fresh ideas, market trends, and strategies, can make a significant change to the future of the Clinical Trial spectrum. Clinical Trial companies can leverage the new technologies and ideas, incorporating important insights into their businesses while positively impacting the overall consumer experience.

To know more, please visit https://ibn.fm/1Qx4j

• Bravo, in February 2024, entered an Asset Purchase Agreement to acquire certain assets of Streaming TVEE Inc. in a deal worth $9.76 million
• Bravo and Pythia Experiences LLC entered an LOI to form a new company in January 2024, with Pythia owning 51%, Bravo owning 49%, Pythia contributing Vidgo Inc. and Bravo contributing a streaming platform
• In September 2023, the company announced it would develop an advertising-based video streaming service and app
• In June 2023, Bravo announced a strategic rebrand, positioning it for growth with a newly defined mission as an entertainment, hospitality and technology company
• The company in May 2023 appointed entertainment industry figures Grant Cramer and Frank Hagan as CEO and President, respectively

Bravo Multinational (OTC: BRVO) actively explores opportunities in the entertainment, hospitality and technology sectors to generate long-term value for its shareholders through high-growth business ventures. Currently focused on pioneering innovative solutions in the digital content landscape, the company’s goal is to provide cutting-edge and diverse content experiences to a global audience.

In February 2024, Bravo finalized a deal to acquire Streaming TVEE Inc.’s assets, marking a pivotal step in establishing its flagship offering, aptly named TVee NOW(TM). The acquired assets provide the company with the technology and foundation to soon offer streaming services including Video-On-Demand (“VOD”) and linear TV, often referred to as traditional broadcast TV, which encompasses cable and satellite networks, through a joint venture with Pythia Experiences.

TVee NOW(TM) plans to offer a wide range of on-demand content, including movies, series, concerts and original programming, at minimal or no cost to viewers. The service, set for beta launch in Q1 2024, will be accessible across various devices, with dedicated apps available on platforms such as Roku, Apple and Google Play stores, reinforcing Bravo’s commitment to innovation and audience accessibility.

The company is based in Virginia Beach, Virginia, with a second office soon opening in Las Vegas, Nevada.

Products

TVee NOW’s streaming service will offer a portion of its content for free, catering to the growing demographic of cord-cutters and aligning with the dynamic landscape of advertising-based video on demand (“AVOD”) streaming. Bravo’s Over-The-Top (“OTT”) streaming platform is specifically crafted to deliver content directly to viewers via the internet, accessible through a browser or freely downloadable apps on smartphones, tablets and smart TVs.

Bravo’s planned strategic approach for content is to first integrate partnered Free Ad-Supported TV (“FAST”) channels, programmatic advertising and a tiered revenue sharing model. Additionally, the company plans to complete the deal with Pythia Experiences, enabling a hybrid model comprised of AVOD, utilizing programmatic advertising through ad servers, and Subscription-based Video-on-Demand (“SVOD”), which the company plans to offer at competitive rates compared to other services. With this model completed, Bravo can bridge the gap until the company can ultimately create its own original content.

Through the asset purchase agreement with Streaming TVEE, Inc., the company obtained exclusive rights, image and likeness, label waivers and exploitation rights for streaming of 117 high-definition music and comedy performances, each offering a director’s cut and multiple camera perspectives. Some of the music artists include Snoop Dogg, H.E.R., Kings of Leon, Alicia Keys and Bone Thugs-N-Harmony, along with comedic performances from Bill Burr, Jim Gaffigan, Kristen Schaal, Rob Delaney and others. This original footage will allow Bravo to recreate shows in diverse formats, which can showcase these concert films in a compelling full-feature format.

Market Opportunity

A report from Fortune Business Insights, a global market research and reporting firm, estimated the global video streaming market at $455.45 billion in 2022. It is projected to grow from $554.33 billion in 2023 to $1.9 trillion by 2030, achieving a CAGR of 19.3% during the forecast period.

Growth drivers, according to the report, include a rising number of users of Video-on-Demand services (YouTube, for example) worldwide and the growing adoption of OTT content providers (like Netflix and Hulu, among many others) by consumers, as well as consumers’ willingness to spend more for streaming video content.

Management Team

Grant Cramer is CEO and Director of Bravo. He has more than 30 years of experience as an actor, writer, director, producer and production executive. As founder and president of Landafar Entertainment and Global Pictures Media, he has overseen development and production of 14 feature films. He executive produced Lone Survivor, November Man and Arctic Dogs. He produced And So It Goes, directed by Rob Reiner and starring Michael Douglas and Diane Keaton. His short film Say Goodnight, Michael won several awards, including the Grand Jury Award at the New York International Independent Film Festival.

Frank Hagan is Bravo’s President and Director. He is an Emmy-nominated producer with over 30 years of experience in the entertainment industry. He is the former Programming Director and GM of QTN. He has produced shows for major networks and companies, including Discovery Channel, History Channel and Relativity Media. Most recently, he served as a consulting producer for Electric Entertainment’s ElectricNOW! and the Saturn Awards and worked as a regular weekly panelist for Outlaw Internet Radio.

Richard Kaiser is CFO and Director of Bravo. He is also CFO at BioForce Nanosciences Holdings Inc. and Gold Rock Holdings Inc. He serves on the board of Element Global Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings Inc. He previously directed investor relations for Royal Standard Minerals Inc. and Scorpio Mining Inc. He was also Head of Corporate Communication and Investor Relations at Air Packaging Technologies Inc. and Puff Pack Industries Inc.

Kayla Slick is COO and Director at Bravo. She has more than 15 years of experience in various industries, including finance, healthcare, technology, retail, hospitality and entertainment. She co-founded The PRIME Symposium and significantly increased revenues for INSIDE Public Accounting. She held positions at Interactive Digital Solutions, where she founded the Sales Development Program and was later promoted to Marketing Communications Director for IDS’ flagship virtual patient observation product.

For more information, visit the company’s website at www.BravoMultinationalInc.com.

NOTE TO INVESTORS: The latest news and updates relating to BRVO are available in the company’s newsroom at https://ibn.fm/BRVO

• Political controversies surrounding threats to the United States’ election integrity and the international aggressions of Russia’s government underscore concerns about the ever-present need to maintain the security of personal and business communications
• Swiss hosted Sekur Private Data Ltd. provides a private and secure communications platform that the company is presently marketing to SMBs in the U.S. with plans to expand to other nations during the coming year
• SWISF provides its encrypted data protection services under Swiss Internet protocol security laws, acknowledging that Switzerland has the strictest data privacy laws in the world
• Sekur boasts a 100 percent-owned infrastructure and proprietary technology to help ensure customers’ data won’t be compromised by third-party operators

Recent salvos fired between ransomware-as-a-service (“RaaS”) operator LockBit and the international coalition of law enforcement agencies that seized servers in eight countries belonging to LockBit or its affiliates (https://ibn.fm/Jtvg5) highlight the global and present nature of concerns about protecting Internet-accessible data.

Ransomware attacks involve the use of virus malware by a cybersphere invader to permanently prevent victims from accessing their own data on their computer systems unless a hefty ransom is paid for the “kidnapped” computer system. In addition to LockBit’s RaaS operation allowing affiliate organizations to rent its services, LockBit has gained attention recently for seeking payment from officials in Fulton County, Georgia, to forestall its threat of publishing sensitive court data related to elections (https://ibn.fm/kQb5d).

Cybersecurity and internet privacy innovator Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) recently highlighted a separate reported data intrusion via email vulnerability affecting the national dialogue over cyber invasion and privacy disruption.

Sekur founder and CEO Alain Ghiai discussed conservative media host Tucker Carlson’s claim that U.S. government agencies “unmasked his internet identity” and leaked emails to the media regarding his preparations to travel to Russia and interview Russian president Vladimir Putin in February of this year, as a consequence of the current White House administration’s dim view of both Putin and Carlson, during Ghiai’s “Weekly Hack” interview with the New To The Street corporate media site (https://ibn.fm/gvllD).

“I would not speculate if it happened or not but … if it did happen, it is for the simple fact that every time you use a Big Tech solution, first of all they have all the rights to read and listen to your (communications),” Ghiai said. “I always tell people that when you give your phone number away to download an application, nothing is private.”

Sekur provides Swiss-hosted solutions for secure communications and secure data management, utilizing a suite of secure cloud-based storage, disaster recovery, document management and other secure communication tools, including encrypted e-mails.

The company recently launched SekurVPN (https://sekur.com/en/vpn) is the world’s first non-big-tech-powered, Swiss-hosted, privacy-focused VPN solution using military-grade security.

“It will encrypt your connection, whether you’re on 5G or wi-fi, and that’s a big asset,” Ghiai told New To The Street on Fox Business TV. “It also will mask your true IP address and give you a Swiss IP address. … In Switzerland, it’s important to know that your IP address is considered your private property. So we can’t mess around with that. We can’t look at your traffic.”

In addition to the data mining-free, Swiss law-regulated establishment of the hub, Sekur boasts a 100 percent-owned infrastructure and proprietary technology. During the upcoming financial quarter, Sekur will launch its planned B2B platform in the United States in conjunction with Ingram Micro, followed by the expansion of its B2B platform to Latin America, the United Arab Emirates and the Kingdom of Saudi Arabia in 2025.

“We are seeing a dramatic increase in cyber-attacks in the USA due to the global conflicts at the present time, and due to the current presidential election campaign for the November 2024 presidential elections. Having our SMBs protected from BEC (Business Email Compromise) attacks is a prime directive,” Ghiai stated in a recent news release announcing the launch of small business marketing efforts (https://ibn.fm/X1Adp). “Average revenue per user is also growing and we expect moving forward to have between a 20% to 50% average revenue per user increase with all new subscribers.”

For more information, visit the company’s website at www.SekurPrivateData.com or product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• D-Wave and NEC Australia announced two new quantum offerings for Australia’s commercial sector, federal and state governments, and academia
• The companies’ new quantum services aim to optimize business operations and can navigate increasingly large datasets to find solutions to real-world problems
• New offerings include a quantum consultancy service and access to D-Wave’s Leap(TM) real-time quantum cloud service

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and NEC Australia recently announced the introduction of two new quantum services to the Australian market, enhancing the quantum computing offerings available to Australia’s commercial sector, federal and state governments, and academia (https://ibn.fm/x9b2Y).

The quantum technology services from NEC Australia and D-Wave can optimize business operations faster than classical computers and navigate increasingly large datasets to find solutions to real-world problems, including logistics and supply chain management, emergency response, financial risk modeling, and drug discovery.

D-Wave and NEC Australia’s joint service offerings include:

• Quantum Consultancy Service: NEC Australia and D-Wave develop and test quantum solutions to help address their customers’ complex challenges using Proof of Concepts (“POCs”) through a refined engagement and delivery methodology. Quantum solutions can be seamlessly migrated into practical business applications. This service, powered by D-Wave’s skilled quantum data scientists, provides hands-on support to help customers understand and transform complex business problems into optimized technical solutions for efficient and cost-effective implementations.
• Leap Quantum Cloud Service: Customers can access D-Wave’s Leap real-time quantum cloud service, enabling them to perform their own research while tapping into the cutting-edge capabilities of quantum computing. This service provides immediate, real-time access to D-Wave’s Advantage(TM) quantum computers and quantum-hybrid solvers, offering enterprise-class performance and scalability.

Murray Thom, Vice President of Quantum Technology Evangelism at D-Wave, said quantum computing is at an important inflection point, as it moves from experimentation to operational use, helping organizations solve their computationally complex problems through real-world applications at scale. “We’re thrilled to team up with NEC to accelerate commercial and government adoption of this transformative technology in Australia and bring its remarkable potential to bear for business and society,” Thom said.

NEC Australia’s Vice President – Technology & Innovation, Ayala Domani, said the company was delighted to work with D-Wave to provide transformative quantum solutions in Australia and ensure that its customers remain agile, efficient, and competitive in an increasingly data-driven world. “Quantum computing is no longer solely the subject of futuristic speculation or found only in top-secret research facilities; it’s a commercially available technology that is revolutionizing business and government operations today, and NEC Australia and D-Wave are proud to lead the way forward in this space,” Domani added.

Domani and Thom also recently spoke at Quantum Australia 2024 in Sydney – representing NEC Australia and D-Wave. Held at the state-of-the-art Winx Stand at Royal Randwick, the three-day in-person program explored the theme “Accelerating Impact: From Research to Commercialisation and Developing Quantum Technology Markets’.”

NEC Australia has 50 years of expertise in delivering complex technical solutions to Australian government agencies and businesses. D-Wave has over 20 years of global leadership in quantum computing solutions – together, NEC Australia and D-Wave have delivered successful local quantum applications since 2021. A shared vision unites the companies in transforming the potential of quantum computing to elevate economic prospects and opportunities for all Australians.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of quantum computing. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of the company’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of its products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that D-Wave is unable to secure or protect the company’s intellectual property; volatility in the price of its securities; the risk that the company’s securities will not maintain the listing on the NYSE; the risk that its restatement of certain previously issued audited and unaudited financial statements or material weaknesses in internal controls could negatively affect investor confidence and raise reputational issues; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.